HURA — TuHURA Biosciences Income Statement
0.000.00%
Last trade - 00:00- $171.23m
- $158.85m
Annual income statement for TuHURA Biosciences, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9.2 | 38.2 | 22.7 | 14.8 | 8.45 |
| Operating Profit | -9.2 | -38.2 | -22.7 | -14.8 | -8.45 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -9.13 | -38.3 | -22.7 | -14.6 | -8.32 |
| Net Income After Taxes | -9.13 | -38.3 | -22.7 | -14.6 | -8.32 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.13 | -38.3 | -22.7 | -14.6 | -8.32 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.13 | -41.5 | -25.1 | -15 | -8.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,354 | -2,772 | -903 | -325 | -11.3 |